Company intelligence / Profile preview
Uvax Bio
Delaware, United Statesuvaxbio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The UVAX-1107 protein nanoparticle vaccine was reported as safe and well-tolerated in healthy volunteers. After two priming doses, 100% of subjects showed robust vaccine-matched IgG antibody responses. The company has begun Phase 1 clinical trials for its HIV-1 vaccine candidates (UVAX-1107 and UVAX-1197) in Australia.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Protein-based vaccinesVirus-like particle vaccinesRecombinant protein nanoparticle vaccines
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
National Institutes of Health (NIH)National Institute for Innovation in Manufacturing BiopharmaceuticalsUniversity of DelawareScripps Research
Beyond the preview
Go deeper on Uvax Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Uvax Bio.